Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Organicell Regenerative Medicine, Inc. (BPSR)
|
Add to portfolio |
|
|
|
| Price: |
$0.03
| | Metrics |
| OS: |
1.49
|
B
| |
|
|
| Market cap: |
$50.7
|
M
| |
|
|
|
Net cash:
|
$816.9
|
k
| |
$0.00
|
per share
|
|
EV:
|
$49.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Oct-31-21 | Oct-31-20 | Oct-31-19 | Oct-31-18 | Oct-31-17 | Oct-31-16 | Oct-31-15 | Oct-31-14 |
| Revenues | 5.6 | 3.1 | 0.1 | 1.0 | 0.6 | 0.2 | 0.1 | 0.0 |
| Revenue growth | 83.2% | 4164.9% | -92.6% | 69.3% | 208.2% | 25.2% | | -100.0% |
| Cost of goods sold | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 |
| Gross profit | 5.0 | 2.7 | -0.2 | 0.8 | 0.4 | 0.1 | 0.1 | 0.0 |
| Gross margin | 90.2% | 87.0% | -319.9% | 78.3% | 71.8% | 48.9% | 66.5% | |
| General and administrative | 17.8 | 15.1 | 3.2 | 4.2 | 9.1 | 1.1 | 0.8 | 0.1 |
| EBIT | -12.7 | -12.4 | -1.8 | -3.5 | -8.6 | -1.0 | -0.7 | 0.0 |
| EBIT margin | -227.7% | -407.0% | -2479.4% | -361.8% | -1516.5% | -564.3% | -504.2% | |
| Pre-tax income | -12.8 | -12.6 | -1.7 | -3.4 | -9.1 | -1.3 | -0.7 | -0.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 30.7% |
| Earnings from continuing ops | -12.8 | -12.6 | -1.7 | -3.5 | -9.0 | -1.1 | -0.7 | -0.1 |
| Earnings from discontinued ops | | | | | | -0.2 | 0.0 | 0.0 |
| Net income | -12.8 | -12.6 | -1.7 | -3.5 | -9.0 | -1.3 | -0.7 | -0.1 |
| Net margin | -227.9% | -411.8% | -2424.7% | -358.9% | -1574.5% | -677.8% | -500.1% | |
| |
| Diluted EPS | ($0.01) | ($0.02) | $0.00 | ($0.01) | ($0.08) | ($0.01) | ($0.01) | $0.00 |
| Shares outstanding (diluted) | 1,059.5 | 670.8 | 467.0 | 271.8 | 108.6 | 100.4 | 134.0 | 150.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|